EGFR and neoplasm: Remarkably, inhibition of FASN by Orlistat in EGFR mutated NSCLC suppresses tumor growth in vitro and in vivo through reducing EGFR palmitoylation but inducing mutant EGFR ubiquitination and subsequent proteasomal degradation [203].